Cognitive function and anticoagulation discontinuation in patients without long-term recurrence after catheter ablation for atrial fibrillation: A substudy of the ALONE-AF trial.

Heart RhythmApr 24, 2026 (epub)
Clinical ResearchCardiology

Ho-Gi Chung, Il-Young Oh, Jun Kim et al.

✦ AI-curated · Sources linked

In 30 seconds

This substudy of the ALONE-AF trial evaluated the cognitive effects of oral anticoagulant (OAC) discontinuation in patients aged 19-80 years without atrial fibrillation recurrence after catheter ablation. The randomized controlled trial found no significant difference in cognitive decline between those who discontinued OAC and those who continued, with a between-group difference in MoCA score change of 0.1.

Key findings

  • Mean total MoCA score increased from 24.4 to 25.0 in the no-OAC group.
  • Mean total MoCA score increased from 24.2 to 24.9 in the OAC group.
  • No significant difference in cognitive score change between no-OAC and OAC groups (P = .759).

Why it matters

Understanding the cognitive implications of OAC therapy discontinuation in patients post-ablation is crucial for managing long-term care and stroke risk. This study suggests that discontinuation may not adversely affect cognitive function in this population.

Source

PubMed · PMID 42035938

Published in Heart Rhythm. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.